Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marcel R.M. van den Brink is active.

Publication


Featured researches published by Marcel R.M. van den Brink.


The New England Journal of Medicine | 2012

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

Jay Patel; Mithat Gonen; Maria E. Figueroa; Hugo F. Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D. Socci; Adriana Heguy; Athena M. Cherry; Gail H. Vance; Rodney R. Higgins; Rhett P. Ketterling; Robert E. Gallagher; Mark R. Litzow; Marcel R.M. van den Brink; Hillard M. Lazarus; Jacob M. Rowe; Selina M. Luger; Adolfo A. Ferrando; Elisabeth Paietta; Martin S. Tallman; Ari Melnick; Omar Abdel-Wahab

BACKGROUND Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML. METHODS We performed a mutational analysis of 18 genes in 398 patients younger than 60 years of age who had AML and who were randomly assigned to receive induction therapy with high-dose or standard-dose daunorubicin. We validated our prognostic findings in an independent set of 104 patients. RESULTS We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in FLT3 (FLT3-ITD), partial tandem duplication in MLL (MLL-PTD), and mutations in ASXL1 and PHF6 were associated with reduced overall survival (P=0.001 for FLT3-ITD, P=0.009 for MLL-PTD, P=0.05 for ASXL1, and P=0.006 for PHF6); CEBPA and IDH2 mutations were associated with improved overall survival (P=0.05 for CEBPA and P=0.01 for IDH2). The favorable effect of NPM1 mutations was restricted to patients with co-occurring NPM1 and IDH1 or IDH2 mutations. We identified genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, and validated the significance of these predictors in an independent cohort. High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67). CONCLUSIONS We found that DNMT3A and NPM1 mutations and MLL translocations predicted an improved outcome with high-dose induction chemotherapy in patients with AML. These findings suggest that mutational profiling could potentially be used for risk stratification and to inform prognostic and therapeutic decisions regarding patients with AML. (Funded by the National Cancer Institute and others.).


Nature | 2015

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile

Charlie G. Buffie; Vanni Bucci; Richard R. Stein; Peter T. McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa A. Kinnebrew; Agnes Viale; Eric R. Littmann; Marcel R.M. van den Brink; Robert R. Jenq; Ying Taur; Chris Sander; Justin R. Cross; Nora C. Toussaint; Joao B. Xavier; Eric G. Pamer

The gastrointestinal tracts of mammals are colonized by hundreds of microbial species that contribute to health, including colonization resistance against intestinal pathogens. Many antibiotics destroy intestinal microbial communities and increase susceptibility to intestinal pathogens. Among these, Clostridium difficile, a major cause of antibiotic-induced diarrhoea, greatly increases morbidity and mortality in hospitalized patients. Which intestinal bacteria provide resistance to C. difficile infection and their in vivo inhibitory mechanisms remain unclear. Here we correlate loss of specific bacterial taxa with development of infection, by treating mice with different antibiotics that result in distinct microbiota changes and lead to varied susceptibility to C. difficile. Mathematical modelling augmented by analyses of the microbiota of hospitalized patients identifies resistance-associated bacteria common to mice and humans. Using these platforms, we determine that Clostridium scindens, a bile acid 7α-dehydroxylating intestinal bacterium, is associated with resistance to C. difficile infection and, upon administration, enhances resistance to infection in a secondary bile acid dependent fashion. Using a workflow involving mouse models, clinical studies, metagenomic analyses, and mathematical modelling, we identify a probiotic candidate that corrects a clinically relevant microbiome deficiency. These findings have implications for the rational design of targeted antimicrobials as well as microbiome-based diagnostics and therapeutics for individuals at risk of C. difficile infection.


Journal of Clinical Investigation | 2010

Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans

Carles Ubeda; Ying Taur; Robert R. Jenq; Michele Equinda; Tammy Son; Miriam Samstein; Agnes Viale; Nicholas D. Socci; Marcel R.M. van den Brink; Mini Kamboj; Eric G. Pamer

Bloodstream infection by highly antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), is a growing clinical problem that increasingly defies medical intervention. Identifying patients at high risk for bacterial sepsis remains an important clinical challenge. Recent studies have shown that antibiotics can alter microbial diversity in the intestine. Here, we characterized these effects using 16s rDNA pyrosequencing and demonstrated that antibiotic treatment of mice enabled exogenously administered VRE to efficiently and nearly completely displace the normal microbiota of the small and large intestine. In the clinical setting, we found that intestinal domination by VRE preceded bloodstream infection in patients undergoing allogeneic hematopoietic stem cell transplantation. Our results demonstrate that antibiotics perturb the normal commensal microbiota and set the stage for intestinal domination by bacteria associated with hospital-acquired infections. Thus, high-throughput DNA sequencing of the intestinal microbiota could identify patients at high risk of developing bacterial sepsis.


Immunity | 2003

Nature's TRAIL—On a Path to Cancer Immunotherapy

Mark J. Smyth; Kazuyoshi Takeda; Yoshihiro Hayakawa; Jacques J. Peschon; Marcel R.M. van den Brink; Hideo Yagita

The TNF-related apoptosis-inducing ligand (TRAIL) offers great promise as a cancer therapeutic. Initially, soluble recombinant versions of the TRAIL molecule have exhibited specific tumoricidal activity against a variety of tumors alone, or in combination with other cancer treatments, and much anticipation awaits the outcomes from early clinical trials. More recently, the natural role of TRAIL has been explored in tumor and allogeneic bone marrow transplantation models in the mouse. Strikingly, the TRAIL effector pathway appears a vital component of immunosurveillance of spontaneous or resident tumor cells by both T cells and NK cells, stimulating more hope that manipulating TRAIL activity is a natural path to improved cancer immunotherapy.


Clinical Infectious Diseases | 2012

Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Ying Taur; Joao B. Xavier; Lauren Lipuma; Carles Ubeda; Jenna D. Goldberg; Asia Gobourne; Yeon Joo Lee; Krista Dubin; Nicholas D. Socci; Agnes Viale; Miguel-Angel Perales; Robert R. Jenq; Marcel R.M. van den Brink; Eric G. Pamer

BACKGROUND Bacteremia is a frequent complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is unclear whether changes in the intestinal microbiota during allo-HSCT contribute to the development of bacteremia. We examined the microbiota of patients undergoing allo-HSCT, and correlated microbial shifts with the risk of bacteremia. METHODS Fecal specimens were collected longitudinally from 94 patients undergoing allo-HSCT, from before transplant until 35 days after transplant. The intestinal microbiota was characterized by 454 pyrosequencing of the V1-V3 region of bacterial 16S ribosomal RNA genes. Microbial diversity was estimated by grouping sequences into operational taxonomic units and calculating the Shannon diversity index. Phylogenetic classification was obtained using the Ribosomal Database Project classifier. Associations of the microbiota with clinical predictors and outcomes were evaluated. RESULTS During allo-HSCT, patients developed reduced diversity, with marked shifts in bacterial populations inhabiting the gut. Intestinal domination, defined as occupation of at least 30% of the microbiota by a single predominating bacterial taxon, occurred frequently. Commonly encountered dominating organisms included Enterococcus, Streptococcus, and various Proteobacteria. Enterococcal domination was increased 3-fold by metronidazole administration, whereas domination by Proteobacteria was reduced 10-fold by fluoroquinolone administration. As a predictor of outcomes, enterococcal domination increased the risk of Vancomycin-resistant Enterococcus bacteremia 9-fold, and proteobacterial domination increased the risk of gram-negative rod bacteremia 5-fold. CONCLUSIONS During allo-HSCT, the diversity and stability of the intestinal flora are disrupted, resulting in domination by bacteria associated with subsequent bacteremia. Assessment of fecal microbiota identifies patients at highest risk for bloodstream infection during allo-HCST.


Journal of Experimental Medicine | 2012

Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation

Robert R. Jenq; Carles Ubeda; Ying Taur; Clarissa C. Menezes; Raya Khanin; Jarrod A. Dudakov; Chen Liu; Mallory L. West; Natalie V. Singer; Michele Equinda; Asia Gobourne; Lauren Lipuma; Lauren F. Young; Odette M. Smith; Arnab Ghosh; Alan M. Hanash; Jenna D. Goldberg; Kazutoshi Aoyama; Bruce R. Blazar; Eric G. Pamer; Marcel R.M. van den Brink

GVHD is associated with significant shifts in the composition of the intestinal microbiota in human and mouse models; manipulating the microbiota can alter the severity of GVHD in mice.


Trends in Immunology | 2009

Thymic involution and immune reconstitution

Heather E. Lynch; Gabrielle L. Goldberg; Ann Patricia Chidgey; Marcel R.M. van den Brink; Richard L. Boyd; Gregory D. Sempowski

Chronic thymus involution associated with aging results in less efficient T-cell development and decreased emigration of naïve T cells to the periphery. Thymic decline in the aged is linked to increased morbidity and mortality in a wide range of clinical settings. Negative consequences of these effects on global health make it of paramount importance to understand the mechanisms driving thymic involution and homeostatic processes across the lifespan. There is growing evidence that thymus tissue is plastic and that the involution process might be therapeutically halted or reversed. We present here progress on the exploitation of thymosuppressive and thymostimulatory pathways using factors such as keratinocyte growth factor, interleukin 7 or sex steroid ablation for therapeutic thymus restoration and peripheral immune reconstitution in adults.


Immunity | 2012

Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease

Alan M. Hanash; Jarrod A. Dudakov; Guoqiang Hua; Margaret H. O’Connor; Lauren F. Young; Natalie V. Singer; Mallory L. West; Robert R. Jenq; Amanda M. Holland; Lucy W. Kappel; Arnab Ghosh; Jennifer J. Tsai; Uttam K. Rao; Nury Yim; Odette M. Smith; Enrico Velardi; Elena B. Hawryluk; George F. Murphy; Chen Liu; Lynette A. Fouser; Richard Kolesnick; Bruce R. Blazar; Marcel R.M. van den Brink

Little is known about the maintenance of intestinal stem cells (ISCs) and progenitors during immune-mediated tissue damage or about the susceptibility of transplant recipients to tissue damage mediated by the donor immune system during graft versus host disease (GVHD). We demonstrate here that deficiency of recipient-derived IL-22 increased acute GVHD tissue damage and mortality, that ISCs were eliminated during GVHD, and that ISCs as well as their downstream progenitors expressed the IL-22 receptor. Intestinal IL-22 was produced after bone marrow transplant by IL-23-responsive innate lymphoid cells (ILCs) from the transplant recipients, and intestinal IL-22 increased in response to pretransplant conditioning. However, ILC frequency and IL-22 amounts were decreased by GVHD. Recipient IL-22 deficiency led to increased crypt apoptosis, depletion of ISCs, and loss of epithelial integrity. Our findings reveal IL-22 as a critical regulator of tissue sensitivity to GVHD and a protective factor for ISCs during inflammatory intestinal damage.


Blood | 2014

The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.

Ying Taur; Robert R. Jenq; Miguel-Angel Perales; Eric R. Littmann; Sejal M. Morjaria; Lilan Ling; Daniel No; Asia Gobourne; Agnes Viale; Parastoo B. Dahi; Doris M. Ponce; Juliet N. Barker; Sergio Giralt; Marcel R.M. van den Brink; Eric G. Pamer

Highly diverse bacterial populations inhabit the gastrointestinal tract and modulate host inflammation and promote immune tolerance. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the gastrointestinal mucosa is damaged, and colonizing bacteria are impacted, leading to an impaired intestinal microbiota with reduced diversity. We examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allo-HSCT at the time of stem cell engraftment. Bacterial 16S rRNA gene sequences were characterized, and microbial diversity was estimated using the inverse Simpson index. Subjects were classified into high, intermediate, and low diversity groups and assessed for differences in outcomes. Mortality outcomes were significantly worse in patients with lower intestinal diversity; overall survival at 3 years was 36%, 60%, and 67% for low, intermediate, and high diversity groups, respectively (P = .019, log-rank test). Low diversity showed a strong effect on mortality after multivariate adjustment for other clinical predictors (transplant related mortality: adjusted hazard ratio, 5.25; P = .014). In conclusion, the diversity of the intestinal microbiota at engraftment is an independent predictor of mortality in allo-HSCT recipients. These results indicate that the intestinal microbiota may be an important factor in the success or failure in allo-HSCT.


Nature | 2015

Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration

Caroline A. Lindemans; Marco Calafiore; Anna Mertelsmann; Margaret H. O’Connor; Jarrod A. Dudakov; Robert R. Jenq; Enrico Velardi; Lauren F. Young; Odette M. Smith; Gillian Lawrence; Juliet Ivanov; Ya-Yuan Fu; Shuichiro Takashima; Guoqiang Hua; Maria Laura Martin; Kevin P. O’Rourke; Yuan-Hung Lo; Michal Mokry; Monica Romera-Hernandez; Lukas E. Dow; Edward E. S. Nieuwenhuis; Noah F. Shroyer; Chen Liu; Richard Kolesnick; Marcel R.M. van den Brink; Alan M. Hanash

Epithelial regeneration is critical for barrier maintenance and organ function after intestinal injury. The intestinal stem cell (ISC) niche provides Wnt, Notch and epidermal growth factor (EGF) signals supporting Lgr5+ crypt base columnar ISCs for normal epithelial maintenance. However, little is known about the regulation of the ISC compartment after tissue damage. Using ex vivo organoid cultures, here we show that innate lymphoid cells (ILCs), potent producers of interleukin-22 (IL-22) after intestinal injury, increase the growth of mouse small intestine organoids in an IL-22-dependent fashion. Recombinant IL-22 directly targeted ISCs, augmenting the growth of both mouse and human intestinal organoids, increasing proliferation and promoting ISC expansion. IL-22 induced STAT3 phosphorylation in Lgr5+ ISCs, and STAT3 was crucial for both organoid formation and IL-22-mediated regeneration. Treatment with IL-22 in vivo after mouse allogeneic bone marrow transplantation enhanced the recovery of ISCs, increased epithelial regeneration and reduced intestinal pathology and mortality from graft-versus-host disease. ATOH1-deficient organoid culture demonstrated that IL-22 induced epithelial regeneration independently of the Paneth cell niche. Our findings reveal a fundamental mechanism by which the immune system is able to support the intestinal epithelium, activating ISCs to promote regeneration.

Collaboration


Dive into the Marcel R.M. van den Brink's collaboration.

Top Co-Authors

Avatar

Robert R. Jenq

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Odette M. Smith

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Alan M. Hanash

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Jarrod A. Dudakov

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Miguel-Angel Perales

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

James W. Young

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Sergio Giralt

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Juliet N. Barker

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Ann A. Jakubowski

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Esperanza B. Papadopoulos

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge